Literature DB >> 26880253

A Mixed-Methods, Randomized, Controlled Feasibility Trial to Inform the Design of a Phase III Trial to Test the Effect of the Handheld Fan on Physical Activity and Carer Anxiety in Patients With Refractory Breathlessness.

Miriam J Johnson1, Sara Booth2, David C Currow3, Lawrence T Lam4, Jane L Phillips5.   

Abstract

CONTEXT: The handheld fan is an inexpensive and safe way to provide facial airflow, which may reduce the sensation of chronic refractory breathlessness, a frequently encountered symptom.
OBJECTIVES: To test the feasibility of developing an adequately powered, multicenter, multinational randomized controlled trial comparing the efficacy of a handheld fan and exercise advice with advice alone in increasing activity in people with chronic refractory breathlessness from a variety of medical conditions, measuring recruitment rates; data quality; and potential primary outcome measures.
METHODS: This was a Phase II, multisite, international, parallel, nonblinded, mixed-methods randomized controlled trial. Participants were centrally randomized to fan or control. All received breathlessness self-management/exercise advice and were followed up weekly for four weeks. Participants/carers were invited to participate in a semistructured interview at the study's conclusion.
RESULTS: Ninety-seven people were screened, 49 randomized (mean age 68 years; 49% men), and 43 completed the study. Site recruitment varied from 0.25 to 3.3/month and screening:randomization from 1.1:1 to 8.5:1. There were few missing data except for the Chronic Obstructive Pulmonary Disease Self-Efficacy Scale (two-thirds of data missing). No harms were observed. Three interview themes included 1) a fan is a helpful self-management strategy, 2) a fan aids recovery, and 3) a symptom control trial was welcome.
CONCLUSION: A definitive, multisite trial to study the use of the handheld fan as part of self-management of chronic refractory breathlessness is feasible. Participants found the fan useful. However, the value of information for changing practice or policy is unlikely to justify the expense of such a trial, given perceived benefits, the minimal costs, and an absence of harms demonstrated in this study.
Copyright © 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breathlessness; RCT; fan; nonpharmacological; palliative care; semistructured interviews

Mesh:

Year:  2016        PMID: 26880253     DOI: 10.1016/j.jpainsymman.2015.11.026

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  5 in total

1.  Contributions of a hand-held fan to self-management of chronic breathlessness.

Authors:  Tim Luckett; Jane Phillips; Miriam J Johnson; Morag Farquhar; Flavia Swan; Teresa Assen; Priyanka Bhattarai; Sara Booth
Journal:  Eur Respir J       Date:  2017-08-17       Impact factor: 16.671

2.  Fooling the brain to alleviate dyspnoea.

Authors:  Capucine Morélot-Panzini
Journal:  Eur Respir J       Date:  2017-08-17       Impact factor: 16.671

3.  A feasibility cluster randomised controlled trial of a paramedic-administered breathlessness management intervention for acute-on-chronic breathlessness (BREATHE).

Authors:  Matthew Northgraves; Judith Cohen; Victoria Allgar; David Currow; Simon Hart; Kelly Hird; Andrew Hodge; Miriam Johnson; Suzanne Mason; Flavia Swan; Ann Hutchinson
Journal:  ERJ Open Res       Date:  2021-03-29

Review 4.  Evidence-based management approaches for patients with severe chronic obstructive pulmonary disease (COPD): A practice review.

Authors:  Yu Fu; Emma J Chapman; Alison C Boland; Michael I Bennett
Journal:  Palliat Med       Date:  2022-03-20       Impact factor: 5.713

5.  Nursing support for symptoms in patients with cancer and caregiver burdens: a scoping review protocol.

Authors:  Jun Kako; Masamitsu Kobayashi; Yusuke Kanno; Kohei Kajiwara; Kimiko Nakano; Miharu Morikawa; Yoshinobu Matsuda; Yoichi Shimizu; Megumi Hori; Mariko Niino; Miho Suzuki; Taichi Shimazu
Journal:  BMJ Open       Date:  2022-09-14       Impact factor: 3.006

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.